These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9598507)

  • 1. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
    Noldus J; Graefen M; Huland E; Busch C; Hammerer P; Huland H
    J Urol; 1998 Jun; 159(6):2004-7; discussion 2007-8. PubMed ID: 9598507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations.
    Chan LW; Stamey TA
    J Urol; 1998 Jun; 159(6):1998-2003. PubMed ID: 9598506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
    Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Ko JL; Hsieh YS
    Jpn J Clin Oncol; 2002 Dec; 32(12):536-42. PubMed ID: 12578903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
    Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
    Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
    Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS
    J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
    Pettaway CA; Troncoso P; Ramirez EI; Johnston DA; Steelhammer L; Babaian RJ
    J Urol; 1998 Aug; 160(2):437-42. PubMed ID: 9679893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer.
    Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Id H'Mammed Y; de Torres IM
    Int J Biol Markers; 2002; 17(4):239-43. PubMed ID: 12521127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
    Pound CR; Partin AW; Epstein JI; Walsh PC
    Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.